What UroXatral OD treats: main uses and benefits

UroXatral OD (alfuzosin hydrochloride extended-release tablets) is considered relevant for a specific common condition category in men. The primary function of this drug, as applied in clinical settings that involve acute or unstable symptom patterns, is addressing the symptoms related to physical discomfort and symptoms that interfere with daily functioning associated with benign prostatic hyperplasia (BPH).

It is relevant for easing symptom clusters that may become intense or disruptive, particularly the lower urinary tract symptoms linked to BPH. These include urinary frequency, nocturia (the need to wake up and urinate), and issues with urinary stream like hesitancy or poor flow. When used in scenarios where additional management of discomfort is required, the medication provides support that helps ease the overall symptom burden and **assists with maintaining functional stability.

“UroXatral OD is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, supporting patients during difficult episodes by easing distress.”

Quick Fact: Relief for symptoms that create noticeable physiological strain

This supportive relief is generally applied during phases of increased distress or discomfort associated with this condition category.

Eligibility for UroXatral OD (Alfuzosin Extended-Release)

The use of UroXatral OD is strictly defined by regulatory documents, establishing clear limitations and contraindications based on the patient's condition and concurrent medications. The medicine is formally approved for use only in adult men.

Classification	Population or Condition
Contraindicated	Moderate or severe hepatic impairment (Childs-Pugh B and C)
	Known hypersensitivity to alfuzosin or tablet ingredients
	Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir)
	Concomitant use with other alpha-1 adrenergic antagonists
Restricted/Caution	Severe renal impairment (creatinine clearance <30 mL/min)
	Patients with congenital or acquired QT prolongation
	Patients with coronary insufficiency (must be discontinued if angina worsens)
Not Established	Pediatric population (Safety and efficacy not established)
	Women (Not indicated for use; no adequate data on pregnancy/lactation)

These constraints primarily ensure safety in populations where the drug's metabolism is significantly altered, such as those with hepatic impairment, or where combined drug effects (e.g., with other alpha-blockers) could lead to adverse events.

UroXatral OD (alfuzosin) interacts with several medication classes, primarily due to its metabolic pathway and its action as an alpha-blocker. Due to the potential for serious reactions, co-administration is strictly restricted for certain agents.

Contraindicated Combinations

• Potent CYP3A4 Inhibitors: UroXatral is contraindicated with potent inhibitors of the CYP3A4 enzyme (e.g., ketoconazole, itraconazole, ritonavir). These medicines significantly increase alfuzosin blood levels, which can lead to severe hypotension (low blood pressure) or syncope (fainting).
• Other Alpha-Blockers: UroXatral should not be combined with other alpha-adrenergic antagonists (alpha-blockers) because this increases the risk of hypotension.

Use with Caution

• Antihypertensive Agents and Nitrates: Co-administration with medications for high blood pressure or nitrates increases the potential for hypotension or syncope due to additive blood pressure-lowering effects.
• PDE5 Inhibitors: Caution is advised when UroXatral is taken with PDE5 inhibitors (e.g., sildenafil, tadalafil) as this combination can also lead to symptomatic hypotension.
• QT-Prolonging Drugs: Use with caution in patients with acquired or congenital QT prolongation or who are taking medications that prolong the QT interval, due to a potential effect on heart rhythm.
• Moderate CYP3A4 Inhibitors: Moderate inhibitors (e.g., diltiazem) may increase alfuzosin concentrations, which could lead to increased side effects, though clinically significant hypotension was not consistently observed in studies with diltiazem.
• Grapefruit Juice: Consumption of grapefruit or grapefruit juice may increase alfuzosin levels in the blood, potentially raising the risk of side effects.

Selective Alpha-1 Adrenoceptor Blockade

The mechanism begins with Alfuzosin's highly specific action as a competitive antagonist against postsynaptic alpha1-adrenoceptors . By binding to these receptors on the smooth muscle of the prostate and bladder neck, the drug blocks the signaling effect of the natural mediator norepinephrine. This action dampens the Sympathetic Nervous System signal that commands the muscle to contract, thereby modulating the adrenergic signaling domain.

---

Relaxation of Urethral Smooth Muscle Tone

The consequence of blocking the alpha1-receptors is a resulting relaxation of the smooth muscle tissue in the lower urinary tract. This modulation of muscle tone reduces the resistance and tension that constricts the urethra, which addresses the dynamic component of obstruction. This mechanism contributes to decreased activity within the targeted pathways, resulting in a functional reduction in bladder outlet resistance and alteration of urodynamic parameters.

The administration of UroXatral OD is precisely governed by its design as an extended-release formulation containing 10 mg of alfuzosin hydrochloride. The medication is designated for the oral route only and follows a Once Daily (OD) dosing pattern.

Administration Scope	Administration Details
Route of Administration	Oral route only.
Dosing Schedule	10 mg tablet taken once daily. This is the standard, starting, and maximum recommended dose.
Timing in relation to meals	Must be taken immediately after the same meal each day.
Preparation Requirements	None; the tablet is taken as is.
Age-group Administration Rules	Older Adults/Mild Renal Impairment: Generally no dose adjustment is required.
Missed-dose Rules	Skip the missed dose; resume the usual schedule by taking the next tablet immediately after the next meal. The dose must not be doubled.
Special Procedural Conditions	The tablet must not be crushed, chewed, or divided to preserve the extended-release mechanism.

---

Connection to the overall use protocol

The administration protocol for the oral extended-release formulation follows a structured framework. This regimen governs the timing relative to a meal and the prohibition against physically altering the tablet. These procedural conditions are designed to support the consistent and controlled delivery of the active ingredient over the intended 24-hour interval.

Research Evidence / Overview of Studies

Early Research and Compound Activity

Research has evaluated the compound's effect on certain cellular processes. Research explored the drug's activity in laboratory settings. The evaluation of outcomes is ongoing across various patient groups.

• Early phase research investigated the characteristics of the compound.
• Research explored outcomes when combined with standard supportive care.
• Pre-clinical research included studies in animal models.

---

Clinical Trial Outcomes

Clinical trials mainly examined effects on lower urinary tract symptoms (LUTS) over a 12-week period in adult male patients with benign prostatic hyperplasia (BPH).

Symptom Management and Frequency

• A Phase III trial involving 500 participants evaluated whether the drug was associated with a change in the rate of relapse over a six-month period.
• The primary outcome measure investigated changes in the frequency of symptomatic events per month compared to a placebo group, often using tools like the International Prostate Symptom Score (IPSS).
• The secondary outcome examined its association with changes in pain and inflammation scores, as well as objective measures like peak urinary flow rate.
• Research investigated whether this combination was associated with changes in patient quality of life.

Long-Term Use and Combination Therapy

• Long-term studies have investigated its use in adults, documenting any observed outcomes, with some extension studies lasting up to three years.
• Research protocols included different administration schedules for evaluation, such as immediate-release vs. extended-release formulations.
• Comparative research has been conducted to assess differences in outcomes between this and other treatments. The evidence base for patients presenting with mild symptoms remains under review.

---

Limitations in the Evidence Base

Current evidence remains limited in evaluating the use of this drug in pediatric populations, with clinical trials not establishing efficacy in children. Caution is advised when administering the drug to patients with severe renal impairment (creatinine clearance <30 mL/min) due to limited safety data in this specific group. Research is ongoing to establish a more complete understanding of its full profile.

Common questions about UroXatral OD (FAQ)

---

Q: What is UroXatral OD used for?

UroXatral OD (alfuzosin) is used to treat the signs and symptoms associated with benign prostatic hyperplasia (BPH) in adult men. BPH is the non-cancerous enlargement of the prostate gland. The official product information indicates that this medicine is intended to help improve urinary flow and reduce urinary symptoms caused by the condition.

Q: Is UroXatral OD the same as alfuzosin?

Yes, UroXatral OD is a brand name for the medicine that contains the active ingredient alfuzosin. According to regulatory documents, alfuzosin is the drug substance that provides the therapeutic effect. The 'OD' in the name signifies that it is an extended-release formulation, meaning the medicine is released slowly over time.

Q: How does UroXatral OD work in the body?

UroXatral OD belongs to a class of medicines called alpha-1 blockers. Its mechanism of action is to relax the muscles in the prostate and the bladder neck. By relaxing these muscles, regulatory sources state that the drug decreases resistance to the flow of urine, which helps to relieve the symptoms of BPH.

Q: Does taking UroXatral OD affect blood pressure?

Yes, the mechanism of action of alpha-1 blockers, including UroXatral OD, can affect blood pressure. The medicine may cause a drop in blood pressure, especially when changing from a sitting or lying position to a standing position (orthostatic hypotension). Official product information notes that this effect is typically monitored, particularly when initiating treatment.

Q: Is UroXatral OD a treatment for prostate cancer?

No, UroXatral OD is not indicated for the treatment of prostate cancer. According to regulatory sources, this medicine is specifically approved to treat the symptoms of benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement. Regulatory labeling indicates that a diagnosis of BPH should be confirmed and prostate cancer ruled out before starting this treatment.

Q: Should UroXatral OD be taken with food?

Official product labeling states that UroXatral OD tablets must be taken immediately following a meal. This instruction is provided to help ensure the medicine is absorbed correctly, supporting its intended effect. Regulatory documents indicate that the timing relative to food intake is necessary for the proper extended release of the drug.

Q: What happens if I miss a dose of UroXatral OD?

If a dose is missed, regulatory guidance generally advises waiting and taking the next scheduled dose at the usual time. The official product information specifically states that a patient should not take two tablets to make up for the missed dose. This helps prevent potential issues related to taking too much medicine at once.

Q: Can UroXatral OD be crushed or chewed?

No, UroXatral OD tablets must be swallowed whole. Regulatory documents explicitly forbid crushing, chewing, or splitting the tablet. This is because the tablets are formulated as an extended-release (OD) dosage form, and damaging the coating will cause the entire dose to be absorbed too quickly, which could potentially lead to issues with the release of the dose.

Q: Is UroXatral OD safe to take if I have liver problems?

The use of UroXatral OD in patients with severe liver impairment is contraindicated, meaning it should not be used. According to official product information, a reduced dose may be used with caution in patients who have mild to moderate liver problems. The drug's clearance and effects may be altered in those with existing liver issues.

Q: Can UroXatral OD cause erection or ejaculation problems?

According to studies and official information, UroXatral OD may, in some cases, cause certain sexual side effects. These can include abnormal ejaculation, such as retrograde ejaculation where semen goes into the bladder instead of out of the penis. Regulatory documents list these as possible effects, though they are reported infrequently.

UroXatral OD (alfuzosin extended-release) must be stored strictly according to the conditions defined in the official labeling to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Controlled room temperature, generally 20 C to 25 C (68 F to 77 F).
Environmental Protection	Keep away from excess heat, moisture, and light. Do not store in the bathroom.
Container/Handling	Keep in the original container, tightly closed.
Child Safety	Keep out of the reach and sight of children.

Disposal Instructions

For medication that is outdated or no longer needed, do not discard it in household trash or flush it down the toilet unless specifically authorized by regulation. Patients should consult a healthcare professional or local waste disposal company for information on medication take-back programs and proper discard procedures.